Algernon Pharmaceuticals submits pre-investigational new drug meeting request with US FDA for its DMT stroke research program
Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) (FRA:AGW) has started formal communication with the US regulator, the Food and Drug Administration (FDA), over its previously announced stroke clinical research program.
The company said it had now filed a pre-IND (Investigational New Drug) meeting request with the agency about its investigation of psychedelic compound DMT as a treatment for stroke.
READ: Algernon Pharmaceuticals updates on timing of topline results for Ifenprodil trial
Specifically, it is asking for direction regarding the use of DMT as an adjunctive treatment with constraint-induced movement therapy (CIMT) to treat upper-limb dysfunction in stroke patients.
Another pre-IND meeting request for its use to treat acute stroke will be filed once additional preclinical work is completed, added Algernon.
CIMT is a therapy, which involves intensive training of the weaker limb while restricting the stronger limb, and has shown it can enhance recovery in patients post-stroke.
CIMT is also used in the treatment of other movement disorders, including traumatic brain injury, multiple sclerosis, and Parkinson’s disease.
Unlike other companies researching such drugs, Algernon has said it will focus on a sub-hallucinogenic, or microdose of DMT given via continuous intravenous administration - the aim being the patient will not have a psychedelic experience.
The company has noted that this approach may also allow for a quicker pathway to regulatory approval, including a Breakthrough Therapy designation from the US FDA.
On March 1 this year, Algernon reported that a Phase 1 study on the psychedelic compound DMT to treat stroke will be carried out by London-based contract research organization (CRO) Hammersmith Medicines Research (HMR).
The Phase 1 study is anticipated to begin as soon as the company has cGMP drug product from its recently appointed manufacturer Dalton Pharma and will evaluate the safety, tolerability and pharmacokinetics of the proposed sub-psychedelic DMT dosages in healthy participants with no prior history of psychedelic exposure. It will provide essential data on the proposed dosing regimen, and also inform the design of the planned Phase 2 trials.
Algernon also recently hired Charles River Laboratories to conduct its preclinical studies of DMT for the stroke research program.
Contact the author at [email protected]
Story by ProactiveInvestors
Source: http://www.proactiveinvestors.com/companies/news/944127/algernon-pharmaceuticals-submits-pre-investigational-new-drug-meeting-request-with-us-fda-for-its-dmt-stroke-research-program-944127.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.
